InvestSMART

Cambium Bio Limited (ASX:CMB)

ALERT: Price-sensitive ASX Announcement for CMB
Current share price for CMB : $0.405 -0.08 (-16.49%)+
Announcement
Release
27 Oct 2025 3:50PM
Price at Release
$0.485
Full Release
download
Summary
Cambium Bio Limited, a regenerative medicine company, has announced its quarterly cash flow report and business update for the period ending 30 September 2025. They secured a significant R&D Tax Incentive approval, offering a 43.5% cash rebate on eligible clinical trial expenditures through FY2027. The company formed strategic partnerships with Keke Medtech, Benta SAS, and Locus Cell, enhancing their commercial potential. Cambium Bio raised A$2.17 million to support Phase 3 trial preparations and maintained disciplined cost management, with a closing cash balance of A$1.32 million. They anticipate further funding through R&D refunds and potential financing avenues to support ongoing operations and their Phase 3 clinical trials.
Key Points
  • R&D Tax Incentive approval secured providing a 43.5% cash rebate.
  • Strategic partnerships with Keke Medtech, Benta SAS, and Locus Cell.
  • Raised A$2.17 million for Phase 3 preparations.
  • Net operating cash outflow of A$0.932 million.
  • Closing cash balance of A$1.32 million.
  • Expected R&D Tax Incentive refund in December 2025.
  • Continued investment in Phase 3 readiness for Elate Ocular®.
  • Efforts to secure further funding through equity, licensing, and financing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.